Business
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe with Commercial Distribution Agreement with Mediconsult AG in SwitzerlandLaunched Real-World Evidence Study in Germany to Further Strengthen the Overall Value Proposition of LYTENAVA™ ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical compan
About this update from Outlook Therapeutics, Inc.
[{"type":"image","alt":"Outlook Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Outlook Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ry.XC5VxIDK5aukGPfsBSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4","width":300,"height":80},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ry.XC5VxIDK5aukGPfsBSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4","width":300,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month ","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe with Commercial Distribution Agreement with Mediconsult AG in Switzerland","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched Real-World Evidence Study in Germany to Further Strengthen the Overall Value Proposition of LYTENAVA™","length":110,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":382,"olType":false},{"type":"text","content":"ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for the second quarter of fiscal year 2026 ended March 31, 2026, and provided a corporate update.","length":345,"tagName":"p"},{"type":"text","content":"“We remain committed to working collaboratively with the FDA to establish a clear path forward toward potential U.S. approval. Our objective is clear: to bring the first FDA-approved ophthalmic formulation of bevacizumab to patients in the United States,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “In addition, we are encouraged by the continued momentum of our European commercial launch of LYTENAVA, highlighted by our expansion into new markets, as well as our recently announced partnership in Switzerlan...